20/20 BIOLABS, INC. Cash and Restricted Cash
20/20 BIOLABS, INC. (AIDX) had Cash and Restricted Cash of $4.55 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-14
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4.55M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4.22M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.03M.
- 2025-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.02M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $4.55M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $4.22M 10-Q · filed 2026-05-20 |
| 2025-12-31 | $1.03M 10-Q · filed 2026-08-14 |
| 2025-06-30 | $1.02M 10-Q · filed 2026-08-14 |
| 2025-03-31 | $1.56M 10-Q · filed 2026-05-20 |
| 2024-12-31 | $1.78M 10-Q · filed 2026-08-14 |
| 2023-12-31 | $4.09M POS AM · filed 2026-04-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGENOMICS INC (NEO) | United States | $2.514B | -35.96 |